AIM

Aim Immunotech

• TipRanks·9h ago

  AIM ImmunoTech granted patent for Ampligen

• NASDAQ·2d ago

  Why Now On-Demand Conference Spotlights Nine Emerging Biotech And Healthcare Stories

• TipRanks·08/24 11:10

  Analysts Are Bullish on Top Healthcare Stocks: AIM ImmunoTech (AIM), Niagen Bioscience (NAGE)

• Dow Jones·08/20 10:12

  AIM ImmunoTech Is Maintained at Buy by Ascendiant Capital

• Dow Jones·08/20 10:12

  AIM ImmunoTech Price Target Cut to $7.00/Share From $9.00 by Ascendiant Capital

• TipRanks·08/12 12:40

  Analysts’ Opinions Are Mixed on These Healthcare Stocks: AIM ImmunoTech (AIM) and Schrodinger (SDGR)

• TipRanks·08/11 13:00

  AIM ImmunoTech CEO Urges Biodefense Military Integration

• NASDAQ·08/10 13:45

  AIM ImmunoTech Reports Q2 Loss, Topline Phase 2 Pancreatic Cancer Data Due In Q1 2027

• Seeking Alpha·08/10 12:40

  AIM ImmunoTech GAAP EPS of -$0.43

• Dow Jones·08/10 12:36

  Press Release: AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen(R) Toward Planned Phase 3 Development in Pancreatic Cancer

• Dow Jones·08/10 12:36

  *AIM ImmunoTech 2Q Loss/Shr 43c >AIM

• TipRanks·08/10 06:01

  Aim Immunotech’s Aggressive Equity Issuance Raises $10.4M but Poses Major Dilution Risk for Shareholders

• TipRanks·08/06 22:16

  AIM ImmunoTech Expands Manufacturing for Ampligen Clinical Supply

• TipRanks·08/05 14:08

  AIM ImmunoTech Ends At-The-Market Equity Program

• NASDAQ·08/04 10:44

  AIM Doses Last Patient Early In Phase 2 DURIPANC For Ampligen In Treating Pancreatic Cancer